Achiko creates and develops new innovations in healthcare diagnostics and technology.
Achiko has created user-friendly diagnostic testing integrated with a digital passport solution for the management of COVID-19. AptameX™ includes DNA aptamer-based technology that is cost effective, chemically synthesised, and widely applicable to the evolving diagnostic field of healthcare. Together with the digital mobile health app Teman Sehat™, Achiko is developing potential technologies that seek to deliver rapid, affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications. AptameX™ and Teman Sehat™ were launched in Indonesia in mid-2021 and AptameX™ received the CE Mark in the European Union in May 2022.
Achiko AG Corporate and Operational Update
Achiko AG Announces Newly Published Annual Report and Accounts for the Year Ended 31 December 2021
Achiko AG – Achiko to publish its 2021 Annual Report by 31 August 2022￼
Achiko AG – Suspension of Trading￼
Achiko AG Announces Annual Results for the Year Ended 31 December 2021
AptameX Production and Commercialisation Update
Achiko AG Production and Sales Update
Achiko AG Research Paper and Commercialisation Update
Achiko AG Strengthens Senior Team with Appointment of Head – GlobeNewswire
Please tell us a little bit about yourself and why you'd like to get connected. Achiko + Orbit Startups will follow up with you via email.